Bausch Health Companies Inc. Restructuring and Related Cost, Expected Number of Positions Eliminated
Bausch Health Companies Inc. (BHC) reported Restructuring and Related Cost, Expected Number of Positions Eliminated of 500 item for the 12-month period ending 2012-12-31, per its 10-K filed 2013-02-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated · last filed 2013-02-28
- Bausch Health Companies Inc. restructuring and related cost, expected number of positions eliminated for the quarter ending 2012-03-31 was 500.00 employee.
- Bausch Health Companies Inc. restructuring and related cost, expected number of positions eliminated for fiscal 2010 was 500.00 employee.
employee
| Period end | Restructuring and Related Cost, Expected Number of Positions Eliminated 3 month | Restructuring and Related Cost, Expected Number of Positions Eliminated 12 month |
|---|---|---|
| 2012-03-31 | 500.00 employee 10-Q · filed 2012-05-04 | |
| 2010-12-31 | 500.00 employee 10-K · filed 2012-02-29 |
item
| Period end | Restructuring and Related Cost, Expected Number of Positions Eliminated 6 month | Restructuring and Related Cost, Expected Number of Positions Eliminated 9 month | Restructuring and Related Cost, Expected Number of Positions Eliminated 12 month |
|---|---|---|---|
| 2012-12-31 | 500.00 item 10-K · filed 2013-02-28 | ||
| 2012-09-30 | 500.00 item 10-Q · filed 2012-11-05 | ||
| 2012-06-30 | 500.00 item 10-Q · filed 2012-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |